Porous membranes for medical implants and methods of manufacture

Information

  • Patent Grant
  • 7815763
  • Patent Number
    7,815,763
  • Date Filed
    Monday, December 19, 2005
    18 years ago
  • Date Issued
    Tuesday, October 19, 2010
    13 years ago
Abstract
The present invention involves porous polymer membranes, suitable for use in medical implants, having controlled pore sizes, pore densities and mechanical properties. Methods of manufacturing such porous membranes are described in which a continuous fiber of polymer is extruded through a reciprocating extrusion head and deposited onto a substrate in a predetermined pattern. When cured, the polymeric material forms a stable, porous membrane suitable for a variety of applications, including reducing emboli release during and after stent delivery, and providing a source for release of bioactive substances to a vessel or organ and surrounding tissue.
Description
FIELD OF THE INVENTION

The present invention relates to porous membranes suitable for covering medical implants such as stents for intravascular delivery, implants covered with such membranes and methods for making the porous membranes.


BACKGROUND OF THE INVENTION

Covered stents for implantation into a body vessel, duct or lumen generally include a stent and a cover attached to the stent. A porous structure of the cover, depending on the porosity, may enhance tissue ingrowth after the covered stent has been implanted. A porous structure affixed to an implantable device also may serve as a reservoir for bioactive components and/or reduce embolization by trapping thrombus against a vessel wall.


Porous membranes for use in medical devices are known in the art. For example, U.S. Pat. No. 4,759,757 to Pinchuk describes the formation of a porous membrane by leaching water soluble inorganic salts incorporated into the membrane to create pores where the salt crystals were initially located. U.S. Pat. No. 6,540,776 to Sanders Millare et al. describes a perforated membrane in which a pattern of interstices is created by removing material, for example, by laser cutting. The foregoing manufacturing methods require at least two process steps to form a porous membrane.


One step processes for forming porous membranes also are known in the art, for example, using spinning techniques. U.S. Patent Application Publication No. 20040051201 to Greenhalgh et al. describes an electrospinning process in which a membrane is formed from a plurality of randomly-oriented, intertangled, non-woven fibrils.


Spinning techniques that produce less random, but non-uniform membranes, also are known. For example, U.S. Pat. No. 4,475,972 to Wong describes a porous polymeric material made by a process in which polymeric fibers are wound on a mandrel in multiple overlying layers. The fibers contain unevaporated solvent when deposited in contact with one another, so that upon evaporation of the solvent the fibers bond together. The fibers laid in one traverse are wound on the mandrel parallel to each other and at an angle with respect to the axis of the mandrel. In the next traverse, the angle of winding is reverse to the previous angle, so that the fibers crisscross each other in multiple layers to form the porous structure.


U.S. Pat. No. 4,738,740 to Pinchuk et al. describes a spinning method similar to that of Wong and further comprising intermittently applying a electrostatic charge to ensure reattachment of broken fibers to the mandrel. U.S. Pat. No. 5,653,747 to Dereume describes a vascular graft with an expandable coating produced by the spinning technique of Wong and having pores that open when the tubular support member expands.


All of the foregoing spinning processes suffer from an inability to tightly control the pore size and pore pattern of the resulting membranes. More specifically, lateral deviation of the fibers using previously known spinning techniques has resulted in unsteady collocation of the fibers and the need to deposit multiple layers to ensure adequate coverage. Consequently, previously-known techniques produce either stiff membranes formed of multiple layers and unsatisfactory porosity, or porous, elastic membranes with insufficient strength.


In view of the foregoing, it would be desirable to provide membranes having controlled porosity, pore pattern and pore distribution.


It further would be desirable to provide a one step manufacturing process to produce membranes having controlled porosity, pore pattern and pore distribution.


It still further would be desirable to provide a one step manufacturing process to produce membranes having controlled porosity and/or pore pattern wherein the membrane includes a bioactive substance that may be eluted from the membrane after implantation.


It also would be desirable to provide manufacturing processes to produce membranes having the desired porosity, pattern and distribution characteristics for use in medical implants.


SUMMARY OF THE INVENTION

In view of the foregoing, it is an object of the present invention to provide membranes for use in medical implants having controlled porosity, pore pattern and pore distribution.


It is another object of this invention to provide a one step manufacturing process to produce membranes having controlled porosity, pore pattern and pore distribution.


It is a further object of the present invention to provide a one step manufacturing process to produce membranes having controlled porosity and/or pore pattern wherein the membrane includes a bioactive substance that may be eluted from the membrane after implantation.


It is also an object of this invention to provide manufacturing processes to produce membranes having the desired porosity, pattern and distribution characteristics for use in medical implants.


These and other objects of the present invention are accomplished by providing a membrane comprising a plurality of fibers that are deposited onto a substrate with a predetermined and reproducible pattern. The substrate may be either a mandrel or a surface of an implantable device, such as a stent. In a preferred embodiment, the fibers comprise a polymer that is sufficiently elastic and robust that the membrane follows the movements of the stent from loading onto a stent delivery system to deployment and implantation, without adversely affecting the performance of the membrane of the stent.


In a preferred embodiment, the membrane is formed using a computer-controller substrate that moves in a precisely controlled and reproducible manner. The polymer used to form the fibers, e.g., a polyurethane or a copolymer thereof, is dissolved in a solvent and extruded through one or more extrusion heads onto a moving substrate. By moving the extrusion head back and forth with a specific velocity along the axis of the substrate, specific filament angles or patterns may be deposited. In accordance with one aspect of the present invention, the number of passes, substrate shape and motion and extrusion head speed and material flow are controlled to provide a predetermined fiber diameter that is deposited to produce desired membrane properties, such as pore size and density.


The membrane may either be fixed on the exterior surface of an implantable device, such as a stent, on the interior surface or both. Where an exterior covering is desired, the membrane may be directly deposited on the implantable device. Alternatively, the covering may be deposited on a mandrel to form a separate component, and then affixed to the implantable device in a later manufacturing step.


In accordance with another aspect of the present invention, the membrane may comprise composite fibers having a viscous sheath co-extruded around a solid core component, or alternatively may comprise co-extruded viscous components. In this manner, a membrane may be created wherein the individual fibers are loaded with a desired bioactive agent, such as a drug, that elutes from the matrix of the membrane without resulting in substantial degradation of the mechanical properties of the membrane.


Methods of manufacturing covered implantable medical devices including the porous membranes of the present invention also are provided.





BRIEF DESCRIPTION OF THE DRAWINGS

Further features of the invention, its nature and various advantages will be more apparent from the accompanying drawings and the following detailed description of the preferred embodiments, in which:



FIG. 1 is a schematic depiction of a membrane manufacturing system constructed in accordance with the principles of the present invention;



FIGS. 2A-2C are perspective views depicting exemplary patterns for depositing fibers onto a moving substrate in accordance with the present invention;



FIG. 3 is a perspective view illustrating a stent covered with the membrane of the present invention;



FIG. 4 is a schematic depiction of a membrane manufacturing process wherein the fibers comprise a core filament having a polymeric sheath; and



FIG. 5 is a schematic depiction of a membrane manufacturing process wherein the fibers comprise a coextrusion of two polymers.





DETAILED DESCRIPTION OF THE INVENTION

The present invention generally relates to medical implants, such as stents, having a porous membrane and the methods of making such membranes and medical implants. In accordance with the present invention, polymer membranes are provided that have well-defined pores based on a controlled deposition of fibers onto a substrate. In this manner a permeable membrane having a predetermined pore size and distribution may be obtained.


Acute as well as late embolization are a significant threat during and after intravascular interventions such as stenting in saphenous vein grafts (SVG) and carotid arteries, where released particles can lead to major cardiac attacks or strokes, respectively. Covered stents for treatment of atherosclerotic lesions constructed according to the present invention comprise a porous membrane bonded to an exterior surface, and interior surface, or both, of a stent. Advantageously, the covered stent of the present invention may serve both to reduce embolization during an interventional procedure and prevent late embolization by tethering emboli and particles to the vessel wall.


The inventive membrane may be engineered to provide any of a number of design properties, including: single and multi-component material composition; loading of one or more physiological (bioactive) substances into the polymer matrix; predetermined isotropic or an-isotropic mechanical properties; and predetermined pore geometry.


In accordance with the principles of the present invention, polymeric material is deposited onto a computer-controlled movable substrate. Controlling the relative location and motion of the material source with regard to the deposition location on the substrate and process parameters, such as material flow and viscosity of the deposited material, permits generation of a multitude of different patterns for the membrane.


The porous membrane of the present invention is sufficiently strong and flexible for use in medical devices, and preferably comprises steps of extruding a continuous fiber-forming biocompatible polymeric material through a reciprocating extrusion head onto a substrate to form an elongated fiber. The fiber is deposited on the substrate in a predetermined pattern in traces having a width of from 5 to 500 micrometers, adjacent traces being spaced apart from each other a distance of between 0 and 500 micrometers.


Preferably, the fibers have a predetermined viscous creep that allows adjacent traces to bond to one another at predetermined contact points upon deposition. The number of overlapping or crossing fibers generally should be less than 5, preferably less than 4, and most preferably 1 or 2. When cured, the biocompatible material provides a stable, porous membrane.


Referring to FIG. 1, apparatus 10 suitable for forming the porous membranes of the present invention comprises polymer extrusion machine 11 coupled to numerically controlled positioning system 12. Computer 13 controls the flow of extrudate 14 through extrusion head 15 as well as relative motion of extrusion head 15 and substrate 16 resulting from actuation of positioning system 12.


Apparatus 10 permits highly-localized deposition of the extrudate with four degrees of freedom onto a substrate to form a membrane. The degrees of freedom are: z—the longitudinal motion of substrate 16 relative to extrusion head 15; φ—the angular movement of substrate 16 relative to extrusion head 15; r—the distance between extrusion head 15 and substrate 16; and θ—the pivotal angle of extrusion head 15. The polymer strands 17 may be deposited onto the substrate under computer control to form any of the patterns described herein below.


In a preferred embodiment, the substrate comprises a rotating mandrel. Polymer is extruded through reciprocating extrusion head 15 representing the first degree of freedom z, and with a controlled distance between the extrusion head and substrate 16, representing the second degree of freedom r. Preferably, the distance between the extrusion head and substrate is between 0 to 50 mm, and more preferably between 0.5 and 20 mm. As the polymer is deposited onto the substrate, the substrate is rotated through a predetermined angle φ, corresponding to the third degree of freedom. In this manner, fibers 17 extruded from extrusion head 15 form a two-dimensional membrane on substrate 16. In addition, by pivoting the extrusion head along its vertical axis, fourth degree of freedom θ may be employed, thus making it possible to deposit more than one filament simultaneously while maintaining a set inter-fiber distance.


The four degrees of freedom discussed above may be independently controlled and if needed, synchronized, to attain a spatial resolution of material deposition having an order of magnitude of microns or higher. Optionally, the second degree of freedom r may be fixed if stable polymer deposition has been achieved. The fourth degree of freedom is not required when extruding only one filament.


Extrusion head 15 may have one or more outlets to deposit an extruded polymer fiber onto substrate 16 in traces having an inter-trace distance ranging between 0 to 1000 micrometers. The width of the individual trace (corresponding to the fiber width) may vary between 5 to 500 micrometers, and more preferably is in the range of 10 to 200 micrometers. Pore size is a function of trace width and inter-trace distance and may be selected by selection of these variables from between 0 (i.e., a tight covering) to 200 micrometers (i.e., to form a filter or tether to trap emboli against a vessel wall). Due to the precise control of fiber deposition, it is possible to create a membrane with desired porosity, strength and flexibility with a very small number of overlapping traces or crossing traces. The number of overlapping or crossing traces in the membrane of the present invention generally should be less than 5, preferably less than 4, and most preferably 1 to 2.


The biocompatible polymer is liquefied either by dissolving the biocompatible material in solvents or by thermally melting the biocompatible material, or both. The viscosity of the liquefied material determines the viscous creep properties and thus final pore size and inter-pore distance when the material is deposited on the substrate. Preferably, the viscous creep is controlled so that desired geometrical and physical properties are met upon deposition. By controlling the viscosity and amount of the deposited material on the substrate and consequently the viscous creep of the polymer before curing, the specified inter-pore distance, pore width and inter-fiber bonding may be achieved. Alternatively, the substrate may be heated to facilitate relaxation and/or curing of the trace width after deposition on the substrate.


Viscosity also may be controlled by adjustment of the distance r of extrusion head 15 relative to substrate 16, the concentration of the solvent in extrudate 14 and/or the heating temperature, ambient pressure, and extrusion parameters. With the viscous creep of the fibers being appropriately controlled, the traces deposited on the substrate will bond to one another at predetermined contact points upon deposition.


A specified pore size of the membrane may be achieved by, but is not limited to, lateral deposition distance between two adjacent material traces, extrusion parameters, and/or extrusion head outlet diameters and extrusion pressure. The latter two parameters also affect the fiber diameter, thus in combination with the fiber deposition pattern selected, permit selection and control of the mechanical properties of the membrane.


Suitable biocompatible materials include but are not limited to polyurethane and copolymers thereof, silicone polyurethane copolymer, polypropylene and copolymers thereof, polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, PTFE and copolymers thereof. Preferred materials for forming membranes of the present invention are polyurethane and copolymers thereof. The polymers may in addition include any biologically active substance having desired release kinetics upon implantation into a patient's body.


Referring now to FIGS. 2A to 2C, exemplary patterns formed by apparatus 10 during deposition of the fibers from extrusion head 15 of the present invention are described. In FIG. 2A, membrane 20 is formed on substrate 16 having diameter D by reciprocating extrusion head 15 longitudinally relative to the longitudinal axis of the substrate, followed by indexed angular movement of the substrate while the extrusion head is held stationary at the ends of the substrate. In this manner, traces 21 having a controlled width and inter-trace spacing may be deposited on the substrate.


Once the longitudinal fibers have been deposited on the substrate, the substrate is rotated 360° while the extrusion head is indexed along the length of the substrate, thereby forming a regular pattern of square or rectangular pores having a predetermined size. Alternatively, if extrusion head 15 is provided with multiple outlets, multiple parallel fibers may be deposited in a single longitudinal pass.



FIG. 2B illustrates alternative membrane pattern 22, wherein the substrate is rotated through precise angular motions during longitudinal translation of the extrusion head. Instead of depositing a straight longitudinal strand, as in the pattern of FIG. 2A, the pattern of FIG. 2B includes a series of “jogs” 23 in each longitudinal filament 24. When adjacent filaments 24 are deposited on the substrate, the contacting portions of the traces bond to one another to define pores 25 having a predetermined size. In this manner, with each longitudinal pass of the extrusion head, a line of pores 25 of predetermined size in formed in a single layer membrane.



FIG. 2C shows another pattern 26 by which the membrane of the present invention may be built up. In this embodiment, positioning system 12 employs two degrees of freedom, z and φ, simultaneously, resulting in a “braid-like” structure. Preferably the extruded fibers retain a high unevaporated solvent content when deposited on substrate 16, so that the fibers fuse to form a unitary structure having a predetermined pore size.


More generally, apparatus 10 may be used to deposit one or more traces of a biocompatible material on substrate 16 while extrusion head 15 is reciprocated along the length of the substrate. An extrusion head having multiple outlets permit the deposition of multiple filaments on the substrate during a single translation of the extrusion head or rotation of the substrate. All translational and rotational motions of the components of apparatus 10 are individually or synchronously controlled by computer 13, thus permitting the membrane to be configured with any desired pattern.


As discussed above with respect to FIGS. 2A-2C, apparatus 10 permits fibers to be deposited with any of a number of possible alternative patterns. By depositing the fibers first in multiple passes longitudinal passes followed by indexed translation of the extrusion head and simultaneous rotation of the substrate, as in FIG. 2A, two trace layers may be generated that cross or overlap to form a membrane having a regular grid of pores. In this case, only one degree of freedom is used at any one time. Alternatively, addressing two degrees of freedom alternatingly, as in the pattern of FIG. 2B, a series of “jogs” may be introduced into the individual fibers. In this case, the traces do not cross but only contact each other, thereby creating a line of pores in a single layer membrane. Still further, by addressing two degrees of freedom simultaneously, a braided structure such as depicted in FIG. 2C may be obtained, in which a specified pore size and shape is attained by varying the distance between two parallel traces of material.


In accordance with one aspect of the present invention, extrusion is performed with chemically or thermally liquefied material, or both. The viscosity of the extrudate may be controlled by the concentration of the solvent, by enhancing evaporation of the solvent from the deposited material trace by means of heating the substrate, by varying the distance r between the extrusion head and the substrate, or by adjusting the extrusion temperature of the material so that a well-defined viscous creep of the material occurs after deposition onto the substrate.


Adjustment of the viscous creep allows fusion of the traces at contact points and thus formation of a two-dimensional membrane having desired mechanical strength characteristics. By appropriately setting these parameters accurate material deposition may be achieved with reduced lateral aberrations of the filaments compared to previously-known membrane manufacturing techniques.


As will of course be understood, the diameter of the substrate should be selected based upon the dimensions of the medical implant or stent to which the membrane is to be affixed. For example, the diameter may be selected based upon the expanded configuration of the medical implant or stent. The implant to be covered may be balloon-expandable or self-expandable. In a preferred embodiment, the implant is a self-expandable stent comprising a superelastic material such as a nickel-titanium alloy.


Referring to FIG. 3, stent 30 covered with membrane 31 of the present invention is described. Stent 30 may comprise any suitable design, such as a plastically deformable slotted tube or self-expanding superelastic structure. Porous membrane 31 may be deposited directly onto the medical implant, such as stent 30 which is employed as the substrate during the membrane deposition process.


Alternatively, the membrane may be deposited on a mandrel and after curing may be bonded in a separate step to the medical implant. In the latter case, thermal drying and/or evaporation of the solvent cures the biocompatible material while on the substrate. Once the membrane has cured sufficiently so that the mechanical properties of the membrane permit it to be removed from the substrate, the membrane may be bonded to a surface of the implant using a solvent, adhesive or thermal technique. In this case, the surface of the implant may be pre-processed to optimize bonding, for example by activation of the surface, coating of the surface with liquified polymer or other appropriate treatments of the surface.


Referring now to FIG. 4, an alternative method of forming a porous membrane, suitable for use in a medical implant, is described. In this embodiment, membrane 40 comprises multi-component fiber 41 including core filament 42 coated with at least second biocompatible material 43 having the same or different chemical, physical, mechanical, biocompatible and or biologically active properties. Material 43 may incorporate one or more biologically active substances that elute into the patient's bloodstream after the medical implant is implanted.


Multi-component fiber 41 may be deposited onto the substrate to form a two-dimensional contiguous structure. The individual components of fiber 41 may be selected to provide different characteristics to the membrane, which may employ any of the pattern designs discussed herein above. For example, core filament 42 may provide mechanical stability, while material 43 may serve as and interface to the biological environment, enhance the adhesive properties for inter-trace bonding and/or enhance bonding of the membrane to the medical implant.


Suitable materials for the core filament include but are not limited to polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, and PTFE and copolymers thereof, and metal wire or fiber glass. Suitable materials for ensheathing core filament 41 include but are not limited to polyurethane and copolymers thereof, silicone polyurethane copolymer, polypropylene and copolymers thereof, polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, PTFE and copolymers thereof.


Referring to FIG. 5, a further alternative method of forming the porous membrane of the present invention is described. In the method depicted in FIG. 5, membrane 50 comprises co-extruded fibers 51 formed of at least first biocompatible material 52 and second biocompatible material 53. Materials 52 and 53 may have the same or different chemical, physical, mechanical, biocompatible and or physiologically active properties. Fibers 51, while illustrated as being co-axially co-extruded, alternatively may be co-extruded co-linearly.


Suitable materials for first material 52 include but are not limited to polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, PTFE and copolymers thereof. Suitable materials for second material 53 include but are not limited to polyurethane and copolymers thereof, silicone polyurethane copolymer, polypropylene and copolymers thereof, polyamides, polyethylenes, PET, PEEK, ETFE, CTFE, PTFE and copolymers thereof.


It should be understood that the present invention is not limited to membranes for use on stents. Rather, the membranes of the present invention may be affixed to any other medical device or implant that is brought into an intracorporal lumen for limited or extended implant durations. Such devices include vascular protection devices to filter emboli that are only transiently introduced into the body. Further applications for such porous membranes may be devices configured to be introduced into other body lumens or ducts, such as the trachea, esophagus, and biliary or urinary lumina.


While preferred illustrative embodiments of the invention are described above, it will be apparent to one skilled in the art that various changes and modifications may be made therein without departing from the invention. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.

Claims
  • 1. A method of making a single-layer porous membrane for use in medical implants comprising: extruding a continuous fiber-forming biocompatible polymeric material through a reciprocating extrusion head to form an elongated fiber;depositing the fiber with a width of 5 to 500 micrometers onto a substrate in a predetermined pattern of non-crossing traces, the traces extending adjacently from a first end to a second end of the substrate, each trace contacting its adjacent traces in an alternating manner, the traces defining a plurality of pores of predetermined sizes, the fiber having a predetermined viscous characteristic that enables adjacent traces to bond to each other; andthermally drying the biocompatible material on the substrate to provide a stable, single-layer porous membrane.
  • 2. The method of claim 1 wherein depositing the fiber comprises depositing the fiber to form a single-layer porous membrane having a thickness equal to the thickness of the fiber.
  • 3. The method of claim 2 wherein depositing the fiber comprises defining pores having an essentially square shape.
  • 4. The method of claim 1 wherein depositing the fiber comprises depositing the fiber with a high unevaporated solvent content to facilitate bonding between adjacent fibers.
  • 5. The method of claim 1, wherein the substrate comprises a vascular implant.
  • 6. The method of claim 5 wherein the vascular implant is a stent.
  • 7. The method of claim 1 wherein extruding a continuous fiber-forming biocompatible polymeric material comprises extrusion coating a polymeric sheath surrounding a solid core filament.
  • 8. The method of claim 1 wherein extruding a continuous fiber-forming biocompatible polymeric material comprises extrusion coating a first polymeric sheath surrounding a second polymeric core filament.
  • 9. The method of claim 1 further comprising removing the porous membrane from the substrate and affixing the porous membrane to a surface of a medical implant.
REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of U.S. patent application Ser. No. 10/859,636, filed Jun. 3, 2004, which is a continuation of U.S. patent application Ser. No. 09/967,789, filed Sep. 28, 2001. This application also claims the benefit of priority from U.S. provisional patent application Ser. No. 60/637,495, filed Dec. 20, 2004.

US Referenced Citations (262)
Number Name Date Kind
4475972 Wong Oct 1984 A
4580568 Gianturco Apr 1986 A
4738740 Pinchuk et al. Apr 1988 A
4743252 Martin, Jr. et al. May 1988 A
4759757 Pinchuk Jul 1988 A
4800882 Gianturco Jan 1989 A
4907336 Gianturco Mar 1990 A
5015253 MacGregor May 1991 A
5041126 Gianturco Aug 1991 A
5059211 Stack et al. Oct 1991 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5116360 Pinchuk et al. May 1992 A
5122154 Rhodes Jun 1992 A
5133732 Wiktor Jul 1992 A
5147370 McNamara et al. Sep 1992 A
5163951 Pinchuk et al. Nov 1992 A
5171262 MacGregor Dec 1992 A
5221261 Termin et al. Jun 1993 A
5282823 Schwartz et al. Feb 1994 A
5292331 Boneau Mar 1994 A
5314444 Gianturco May 1994 A
5370683 Fontaine Dec 1994 A
5378239 Termin et al. Jan 1995 A
5380299 Fearnot et al. Jan 1995 A
5421955 Lau et al. Jun 1995 A
5443458 Eury Aug 1995 A
5443496 Schwartz et al. Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5476508 Amstrup Dec 1995 A
5496277 Termin et al. Mar 1996 A
5514154 Lau et al. May 1996 A
5527354 Fontaine et al. Jun 1996 A
5556414 Turi Sep 1996 A
5569295 Lam Oct 1996 A
5591197 Orth et al. Jan 1997 A
5591224 Schwartz et al. Jan 1997 A
5593417 Rhodes Jan 1997 A
5593442 Klein Jan 1997 A
5603721 Lau et al. Feb 1997 A
5609606 O'Boyle Mar 1997 A
5628788 Pinchuk May 1997 A
5630829 Lauterjung May 1997 A
5632772 Alcime et al. May 1997 A
5639278 Dereume et al. Jun 1997 A
5649952 Lam Jul 1997 A
5651174 Schwartz et al. Jul 1997 A
5653747 Dereume Aug 1997 A
5670161 Healy et al. Sep 1997 A
5674242 Phan et al. Oct 1997 A
5674277 Freitag Oct 1997 A
5693085 Buirge et al. Dec 1997 A
5695516 Fischell et al. Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5700285 Myers et al. Dec 1997 A
5707386 Schnepp-Pesch et al. Jan 1998 A
5707388 Lauterjung Jan 1998 A
5709703 Lukic et al. Jan 1998 A
5709713 Evans et al. Jan 1998 A
5716393 Lindenburg et al. Feb 1998 A
5723003 Winston et al. Mar 1998 A
5723004 Dereume et al. Mar 1998 A
5728158 Lau et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5735892 Myers et al. Apr 1998 A
5735893 Lau et al. Apr 1998 A
5735897 Buirge Apr 1998 A
5738817 Danforth et al. Apr 1998 A
5741325 Chaikof et al. Apr 1998 A
5741327 Frantzen Apr 1998 A
5743874 Fischell et al. Apr 1998 A
5749880 Banas et al. May 1998 A
5755771 Penn et al. May 1998 A
5755772 Evans et al. May 1998 A
5755774 Pinchuk May 1998 A
5755781 Jayaraman May 1998 A
5769884 Solovay Jun 1998 A
5776161 Globerman Jul 1998 A
5776181 Lee et al. Jul 1998 A
5776183 Kanesaka et al. Jul 1998 A
5800526 Anderson et al. Sep 1998 A
5807404 Richter Sep 1998 A
5810868 Lashinski et al. Sep 1998 A
5810870 Myers et al. Sep 1998 A
5810872 Kanesaka et al. Sep 1998 A
5814063 Freitag Sep 1998 A
5817126 Imran Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824045 Alt Oct 1998 A
5824048 Tuch Oct 1998 A
5824054 Khosravi et al. Oct 1998 A
5824059 Wijay Oct 1998 A
5827321 Roubin et al. Oct 1998 A
5836964 Richter et al. Nov 1998 A
5836966 St. Germain Nov 1998 A
5843120 Israel et al. Dec 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5843164 Frantzen et al. Dec 1998 A
5846247 Unsworth et al. Dec 1998 A
5853419 Imran Dec 1998 A
5855598 Pinchuk Jan 1999 A
5855600 Alt Jan 1999 A
5860999 Schnepp-Pesch et al. Jan 1999 A
5861027 Trapp Jan 1999 A
5868781 Killion Feb 1999 A
5871538 Dereume Feb 1999 A
5876449 Starck et al. Mar 1999 A
5876450 Johlin, Jr. Mar 1999 A
5895406 Gray et al. Apr 1999 A
5897589 Cottenceau et al. Apr 1999 A
5922021 Jang Jul 1999 A
5928248 Acker Jul 1999 A
5938682 Hojeibane et al. Aug 1999 A
5948018 Dereume et al. Sep 1999 A
5954743 Jang Sep 1999 A
5968091 Pinchuk et al. Oct 1999 A
5980552 Pinchasik et al. Nov 1999 A
5984965 Knapp et al. Nov 1999 A
6017365 Von Oepen Jan 2000 A
6019789 Dinh et al. Feb 2000 A
6027526 Limon et al. Feb 2000 A
6033433 Ehr et al. Mar 2000 A
6033434 Borghi Mar 2000 A
6033435 Penn et al. Mar 2000 A
6039756 Jang Mar 2000 A
6048361 Von Oepen Apr 2000 A
6059811 Pinchasik et al. May 2000 A
6068656 Von Oepen May 2000 A
6071308 Ballou et al. Jun 2000 A
6086610 Duerig et al. Jul 2000 A
6099561 Alt Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6113627 Jang Sep 2000 A
6117165 Becker Sep 2000 A
6117535 Szycher et al. Sep 2000 A
6123721 Jang Sep 2000 A
6132460 Thompson Oct 2000 A
6165212 Dereume et al. Dec 2000 A
6174326 Kitakoa et al. Jan 2001 B1
6179868 Burpee et al. Jan 2001 B1
6190403 Fischell et al. Feb 2001 B1
6193744 Ehr et al. Feb 2001 B1
6193747 Von Oepen Feb 2001 B1
6200334 Jang Mar 2001 B1
6200335 Igaki Mar 2001 B1
6203569 Wijay Mar 2001 B1
6231598 Berry et al. May 2001 B1
6231600 Zhong May 2001 B1
6241762 Shanley Jun 2001 B1
6253443 Johnson Jul 2001 B1
6258116 Hojeibane Jul 2001 B1
6261318 Lee et al. Jul 2001 B1
6264688 Herklotz et al. Jul 2001 B1
6264690 Von Oepen Jul 2001 B1
6270524 Kim Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6299604 Ragheb et al. Oct 2001 B1
6299635 Frantzen Oct 2001 B1
6325825 Kula et al. Dec 2001 B1
6331189 Wolinsky et al. Dec 2001 B1
6332089 Acker et al. Dec 2001 B1
6340366 Wijay Jan 2002 B2
6348065 Brown et al. Feb 2002 B1
6377835 Schoenberg et al. Apr 2002 B1
6395020 Ley et al. May 2002 B1
6436132 Patel et al. Aug 2002 B1
6451049 Vallana et al. Sep 2002 B2
6485508 McGuinness Nov 2002 B1
6488702 Besselink Dec 2002 B1
6491718 Ahmad Dec 2002 B1
6503272 Duerig et al. Jan 2003 B2
6506211 Skubitz et al. Jan 2003 B1
6508834 Pinchasik et al. Jan 2003 B1
6540776 Sanders Millare et al. Apr 2003 B2
6558415 Thompson May 2003 B2
6572646 Boylan et al. Jun 2003 B1
6589276 Pinchasik et al. Jul 2003 B2
6602285 Von Oepen et al. Aug 2003 B1
6607554 Dang et al. Aug 2003 B2
6616689 Ainsworth et al. Sep 2003 B1
6624097 Martin et al. Sep 2003 B2
D481139 Seibold et al. Oct 2003 S
6629994 Gomez et al. Oct 2003 B2
6679911 Burgermeister Jan 2004 B2
6682554 Oepen et al. Jan 2004 B2
6723119 Pinchasik et al. Apr 2004 B2
6730252 Teoh et al. May 2004 B1
6740114 Burgermeister May 2004 B2
6749629 Hong et al. Jun 2004 B1
6755856 Fierens et al. Jun 2004 B2
6776794 Hong et al. Aug 2004 B1
6786922 Schaeffer Sep 2004 B2
6790227 Burgermeister Sep 2004 B2
6796999 Pinchasik Sep 2004 B2
6821292 Pazienza et al. Nov 2004 B2
6846323 Yip et al. Jan 2005 B2
6875228 Pinchasik et al. Apr 2005 B2
6881222 White et al. Apr 2005 B2
6913619 Brown et al. Jul 2005 B2
6916336 Patel et al. Jul 2005 B2
6929660 Ainsworth et al. Aug 2005 B1
6942689 Majercak Sep 2005 B2
6955686 Majercak et al. Oct 2005 B2
6998060 Tomonto Feb 2006 B2
7029493 Majercak et al. Apr 2006 B2
7060093 Dang et al. Jun 2006 B2
7128756 Lowe et al. Oct 2006 B2
7141062 Pinchasik et al. Nov 2006 B1
7329277 Addonizio et al. Feb 2008 B2
7520892 Ainsworth et al. Apr 2009 B1
7625398 Clifford et al. Dec 2009 B2
20010027339 Boatman et al. Oct 2001 A1
20010049549 Boylan et al. Dec 2001 A1
20020019660 Gianotti et al. Feb 2002 A1
20020035394 Fierens et al. Mar 2002 A1
20020065549 White et al. May 2002 A1
20020107560 Richter Aug 2002 A1
20020111669 Pazienza et al. Aug 2002 A1
20020151964 Smith et al. Oct 2002 A1
20020169499 Zilla et al. Nov 2002 A1
20030055487 Calisse Mar 2003 A1
20030083736 Brown et al. May 2003 A1
20030114918 Garrison et al. Jun 2003 A1
20030120334 Gerbeding Jun 2003 A1
20040051201 Greenhalgh et al. Mar 2004 A1
20040093073 Lowe et al. May 2004 A1
20040102836 Fischell et al. May 2004 A1
20040126405 Sahatjian et al. Jul 2004 A1
20040193250 Von Oepen et al. Sep 2004 A1
20040230293 Yip et al. Nov 2004 A1
20040236407 Fierens et al. Nov 2004 A1
20040243220 Gianotti et al. Dec 2004 A1
20050004650 Oepen et al. Jan 2005 A1
20050004651 Von Oepen et al. Jan 2005 A1
20050004655 Von Oepen et al. Jan 2005 A2
20050004658 Oepen et al. Jan 2005 A1
20050004659 Von Oepen et al. Jan 2005 A1
20050004662 Von Oepen et al. Jan 2005 A1
20050043777 Von Oepen et al. Feb 2005 A1
20050043778 Von Oepen et al. Feb 2005 A1
20050075716 Yan Apr 2005 A1
20050222671 Schaeffer et al. Oct 2005 A1
20060015173 Clifford et al. Jan 2006 A1
20060106452 Niermann May 2006 A1
20060142844 Lowe et al. Jun 2006 A1
20060184232 Gianotti et al. Aug 2006 A1
20060206195 Calisse Sep 2006 A1
20060247759 Burpee et al. Nov 2006 A1
20070021827 Lowe et al. Jan 2007 A1
20070021834 Young et al. Jan 2007 A1
20070135891 Schneider Jun 2007 A1
20070179593 Fierens et al. Aug 2007 A1
20070179601 Fierens et al. Aug 2007 A1
20070213800 Fierens et al. Sep 2007 A1
20070299505 Gregorich et al. Dec 2007 A1
20080294239 Casey Nov 2008 A1
20080294240 Casey Nov 2008 A1
20090163992 Osman et al. Jun 2009 A1
20090163996 Bregulla Jun 2009 A1
20090163997 Casey Jun 2009 A1
20090163998 Casey Jun 2009 A1
Foreign Referenced Citations (54)
Number Date Country
2309079 Nov 2004 CA
0699451 Mar 1996 EP
0709067 May 1996 EP
0808614 Nov 1997 EP
0928605 Jul 1999 EP
0950386 Oct 1999 EP
0983753 Mar 2000 EP
1042997 Oct 2000 EP
1095631 May 2001 EP
1516600 Mar 2005 EP
2774279 Aug 1999 FR
2344053 May 2000 GB
7-24072 Jan 1995 JP
08-206226 Aug 1996 JP
09-010318 Jan 1997 JP
10-328216 Dec 1998 JP
11-299901 Feb 1999 JP
2000312721 Nov 2000 JP
WO9117789 Nov 1991 WO
WO9621404 Jul 1996 WO
WO9625124 Aug 1996 WO
WO9712563 Apr 1997 WO
WO9712564 Apr 1997 WO
WO9714375 Apr 1997 WO
WO9832412 Jul 1998 WO
WO9847447 Oct 1998 WO
WO9907308 Feb 1999 WO
WO9917680 Apr 1999 WO
WO9923976 May 1999 WO
WO9938456 Aug 1999 WO
WO9938458 Aug 1999 WO
WO9939660 Aug 1999 WO
WO9949928 Oct 1999 WO
WO0013611 Mar 2000 WO
WO0032241 Jun 2000 WO
WO0045744 Aug 2000 WO
WO0053119 Sep 2000 WO
WO0101885 Jan 2001 WO
WO0182835 Nov 2001 WO
WO0226164 Apr 2002 WO
WO02064061 Aug 2002 WO
WO02064065 Aug 2002 WO
WO02094127 Nov 2002 WO
WO03009779 Feb 2003 WO
WO03057076 Jul 2003 WO
WO2004087015 Oct 2004 WO
WO2006055533 May 2006 WO
WO2006066886 Jun 2006 WO
WO2006099449 Sep 2006 WO
WO2008042618 Apr 2008 WO
WO2008142566 Nov 2008 WO
WO2009046973 Apr 2009 WO
WO2009080326 Jul 2009 WO
WO2009080327 Jul 2009 WO
Related Publications (1)
Number Date Country
20060175727 A1 Aug 2006 US
Provisional Applications (1)
Number Date Country
60637495 Dec 2004 US
Continuations (1)
Number Date Country
Parent 09967789 Sep 2001 US
Child 10859636 US
Continuation in Parts (1)
Number Date Country
Parent 10859636 Jun 2004 US
Child 11313110 US